Phoenix Life Announces $40 Million Capital Raise in Conjunction
with TABOR Family Office Conference
DENVER,
CO, May 1, 2019 -- InvestorsHub NewsWire
-- Phoenix
Life Sciences International Limited (OTC: PLSI) ("Phoenix Life" or the
"Company"), an adaptive healthcare solutions company, today
announced that it will be executing a $40 million capital raise and
presenting at the TABOR Family Office Conference in Sea Island,
Georgia.
The offering terms
of Phoenix Life's capital raise include a $40 million raise with a
minimum subscription of 2,000 shares, or $25,000. In total, the
Company is offering 3.2 million shares of the Company's common
stock at a purchase price of $12.50 per share to accredited
investors, including qualified family offices and institutional
investors. Phoenix Life intends to dedicate the proceeds of this
capital raise to furthering the company's international expansion,
including the Global Production Facility and National Network of
Community Clinics and Dispensing Pharmacies.
"We are excited to
share this important news after just recently completing our annual
report filings," said Phoenix Life CEO and Founder, Martin Tindall.
"With this capital raise, we will be able to bring online 100 acres
of cultivation capacity and pharmaceutical production of Phoenix
Metabolic and other Phoenix Life products to supply much needed
products for up to 1,000,000 patients. The first of a multi-phase
approach to transforming the future of global
healthcare."
The TABOR Family
Office Conference is invitation-only and will consist of
approximately 50 high net worth Family Offices and 25 to 30
Investment Managers. Phoenix Life is one of the few companies
chosen to present at the conference.
TABOR Capital
Conferences is an alternative investment conference organizer. The
Firm's key objective is to bring Elite Investment Managers together
with Investors in small forums that allow for meaningful
discussions and the opportunity to foster new relationships.
TABOR'S goal is to host small, specialized conferences that are
beneficial for all attendees and ultimately provide value after the
completion of each event.
For more
information on Phoenix Life's capital raise and accompanying
Private Placement Memorandum, please visit the company's Investor
Portal at
http://invest.phoenixlife.co
To learn more about
Phoenix Life Sciences International, please visit
https://phoenixlife.co/.
###
About Phoenix
Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare
solutions company. Our business is to advance research and
integrate programs and manufacturing of products that target and
treat diabetes, pain, cancer, and address psychological,
gastrointestinal, autoimmune, neurological and sleep disorders. We
strive to create partnerships and integrate these programs for
human health into communities worldwide as part of our Global
Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the "Companies") may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
"plan", "forecast", "anticipates", "estimate", "project", "intend",
"expect", "should", "believe," and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to, known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in the Company's filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to the Companies herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. The Companies disclaim any obligation to update
forward-looking statements contained in this press release, except
as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements
have not been evaluated by the FDA and therefore the products sold
by Phoenix Life Sciences International are not available in the
U.S.
LEGAL
DISCLOSURE
Phoenix Life
Sciences International does not sell or distribute any products in
the United States that are in violation of the United States
Controlled Substances Act (US.CSA). This company does not grow,
sell, and distribute cannabis-based products in the United States
and is solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States.
Investor
Contact:
Phone:
1.888.717.5655 or international +1.720.699.7222
E-mail:
investor.relations@phoenixlife.co
Media
Contact:
Kathryn
Reinhardt
CMW
Media
Kathryn@cmwmedia.com
619-972-3089